Released on: January 7, 2008, 10:52 am

Press Release Author: GTCBIO

Industry: Pharmaceuticals

Press Release Summary: Thomas Schall, President & CEO of ChemoCentryx will give a
presentation entitled "Inhibition of CCR9 as a Therapeutic Approach: Beyond the
Small Intestine" at GTCbio's 6th Cytokines and Inflammation (January 28-29, 2008,
Orlando, Florida.)

Press Release Body: FOR IMMEDIATE RELEASE
January 7, 2008


CEO of ChemoCentryx to Present at GTCbio's 6th Cytokines and Inflammation (January
28-29, 2008, Orlando, Florida

Thomas Schall, President & CEO of ChemoCentryx will give a presentation entitled
"Inhibition of CCR9 as a Therapeutic Approach: Beyond the Small Intestine" at
GTCbio's 6th Cytokines and Inflammation (January 28-29, 2008, Orlando, Florida.)

CCR9 is a chemokine receptor known to play a pivotal role in migration of T-cells to
the mucosal surface of the gut. It is well established that CCR9 is critical for
T-cell homing to the small intestine. ChemoCentryx has recently found that CCR9 is
also critical for development of ulcerative colitis in animal models, indicating a
role for this chemokine receptor in cell migration to the large bowel.

One of the earliest investigators in the field of chemokine biology, Dr. Thomas
Schall founded ChemoCentryx in 1997 to focus on the discovery and development of
chemokine-based therapeutics. Prior to founding ChemoCentryx, Dr. Schall spent
several years at a division of Schering Plough, the DNAX Research Institute, where
he made fundamental contributions to the understanding of chemokines and their
receptors in human in disease. Before that Dr. Schall served for some years as a
scientist with Genentech, Inc. During his scientific career, Dr. Schall published
over 100 articles in noted peer-reviewed journals.

The conference also features presentations from other leading organizations such as
Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer,
Roche, Schering Plough, and many more. The full agenda is available online at
www.gtcbio.com.

GTCbio's 6th Cytokines and Inflammation conference will take place on January 28-29,
2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines
Signaling and Regulation, Inflammation and Cancer, Technological Developments in
Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors

For more information including a detailed agenda, exhibitor opportunities and
registration information visit http://gtcbio.com/userAgenda.aspx?id=115



ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com







Web Site: http://

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com